

## Zambia

### Support for Vaccine: DTP-HepB-Hib This Decision Letter sets out the Programme Terms of a Programme.

<b>1.</b>	<b>Country:</b>	Zambia																				
<b>2.</b>	<b>Vaccine grant number:</b>	0715-ZMB-04A-X, 16-ZMB-04a-X, 17-ZMB-04a-X, 1821-ZMB-04a-X, ZMB-Lumpsum-1																				
<b>3.</b>	<b>Date of Decision Letter:</b>	30 September 2019																				
<b>4.</b>	<b>Date of the Partnership Framework Agreement:</b>	22 October 2014																				
<b>5.</b>	<b>Programme title:</b>	New Vaccine Support (NVS), DTP-HepB-Hib, Routine																				
<b>6.</b>	<b>Vaccine type:</b>	DTP-HepB-Hib																				
<b>7.</b>	<b>Requested product presentation and formulation of vaccine:</b>	Penta, 1 dose(s) per vial, LIQUID																				
<b>8.</b>	<b>Programme Duration:<sup>1</sup></b>	2004-2021																				
<b>9.</b>	<b>Programme Budget (indicative):<sup>2</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)																				
		2004-2019	2020	2021	2022	2023	2024	Total <sup>2</sup>														
	Programme Budget (US\$)	72,108,084	1,364,500	1,893,000	-	-	-	75,365,584														
<b>10.</b>	<b>Vaccine introduction grant</b>	<table border="1" style="width: 100%; border-collapse: collapse; margin-bottom: 10px;"> <thead> <tr> <th colspan="3" style="text-align: center;">Approval</th> </tr> <tr> <th style="width: 15%;">Year</th> <th style="width: 45%;">Grant Number</th> <th style="width: 40%;">Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">2002</td> <td style="text-align: center;">ZMB-Lumpsum-1</td> <td style="text-align: right;">100,000</td> </tr> </tbody> </table> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th colspan="2" style="text-align: center;">Disbursement</th> </tr> <tr> <th style="width: 50%;">Disbursement date</th> <th style="width: 50%;">Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">11 February, 2002</td> <td style="text-align: right;">100,000</td> </tr> </tbody> </table>						Approval			Year	Grant Number	Amount (US\$)	2002	ZMB-Lumpsum-1	100,000	Disbursement		Disbursement date	Amount (US\$)	11 February, 2002	100,000
Approval																						
Year	Grant Number	Amount (US\$)																				
2002	ZMB-Lumpsum-1	100,000																				
Disbursement																						
Disbursement date	Amount (US\$)																					
11 February, 2002	100,000																					
<b>11.</b>	<b>Product switch grant</b>	Not applicable																				
<b>12.</b>	<b>Indicative Annual Amounts:<sup>3</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)																				
	<b>Type of supplies to be purchased with Gavi funds</b>	<b>2004-2019</b>																				
	Number of vaccine doses		1,111,200																			

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the amount that Gavi has approved.

Annual Amounts (US\$)	72,108,084	1,364,500						
<b>13. Procurement agency:</b>	UNICEF. The Country shall release its co-financing payments each year to UNICEF.							
<b>14. Self-procurement:</b>	Not applicable							
<b>15. Co-financing obligations:</b>	According to the co-financing policy, the Country falls within the group: Preparatory transition phase							
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.								
Type of supplies to be purchased with Country funds in each year	<b>2020</b>	<b>2021</b>						
Number of vaccine doses	247,800	408,900						
Number of AD syringes	259,500	428,400						
Number of re-constitution syringes	-	-						
Number of safety boxes	2,875	4,725						
Value of vaccine doses (US\$)	287,336	474,286						
Total co-financing payments (US\$) (including freight)	316,000	521,500						
<b>16. Operational support for campaigns:</b>	Not applicable							
<b>17. Additional Reporting Requirements:</b>	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul> </td> <td> 31 March 2020  15 May 2020 </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>			Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	31 March 2020 15 May 2020	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
	Due dates							
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	31 March 2020 15 May 2020							
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat							

**18. Financial clarifications:**

Not applicable

**19. Other conditions:**

Not applicable

Signed by,

**On behalf of Gavi**



Thabani Maphosa,  
Managing Director, Country Programmes  
30 September 2019